Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens

References

• Kyu HH, Abate D, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1859–1922. doi:10.1016/S0140-6736(18)32335-3
   PubMed Web of Science ®Google Scholar
• Liu G, Kang S, Wang X, Shang F. Cost-effectiveness analysis of atezolizumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer with different PD-L1 expression status. Front Oncol. 2021;11:669195 doi:10.3389/fonc.2021.669195
   PubMed Web of Science ®Google Scholar
• Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018. Global Cancer Statistics?. Cancer Commun. 2019;39(1):22 doi:10.1186/s40880-019-0368-6
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016. JAMA Oncol. 2018;4(11):1553. doi:10.1001/jamaoncol.2018.2706
   PubMed Web of Science ®Google Scholar
• Cao W, Chen H, Yu Y, Li N, Chen W. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Med J-Peking. 2021;134(7):783–791. doi:10.1097/CM9.0000000000001474
   PubMed Web of Science ®Google Scholar
• Xiang G, Gu L, Chen X, et al. Economic evaluation of first-line camrelizumab for advanced non-small-cell lung cancer in China. Front Public Health. 2021;9:743558. doi:10.3389/fpubh.2021.743558
   PubMed Web of Science ®Google Scholar
• Zhou D, Luo X, Zhou Z, et al. Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China. Front Pharmacol. 2022;13:880280 doi:10.3389/fphar.2022.880280
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang H, Li L, Feng L, Liu Q. Cost-effectiveness analysis of pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer in China. Risk Manage Healthc Policy. 2023;16:1849–1857. doi:10.2147/RMHP.S429394
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi:10.3322/caac.21565
   PubMed Web of Science ®Google Scholar
• Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518–2527. doi:10.1200/JCO.19.00934
   PubMed Web of Science ®Google Scholar
• Wu B, Lu S. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. Translational Lung Cancer Res. 2020;9(5):1770–1784. doi:10.21037/tlcr-19-605
   PubMed Web of Science ®Google Scholar
• Han J, Tian K, Yang J, Gong Y. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: an updated PACIFIC trial-based cost-effectiveness analysis. Lung Cancer. 2020;146:42–49. doi:10.1016/j.lungcan.2020.05.011
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang Z, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology Program by innovent anti-PD-1-11). J Thorac Oncol. 2020;15(10):1636–1646. doi:10.1016/j.jtho.2020.07.014
   PubMed Web of Science ®Google Scholar
• Sun J, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. doi:10.1016/S0140-6736(21)01234-4
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X
   PubMed Web of Science ®Google Scholar
• Lee SM, Schulz C, Prabhash K, et al. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. Lancet. 2023;402(10400):451–463. doi:10.1016/S0140-6736(23)00774-2
   PubMed Web of Science ®Google Scholar
• Yang Y, Xia Y, Su C, et al. Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China. J Cancer Res Clin. 2023;149(8):4205–4214. doi:10.1007/s00432-022-04258-w
   PubMed Web of Science ®Google Scholar
• Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Center. 2024. doi:10.1016/j.jncc.2024.01.006
   Google Scholar
• Rui M, Wang Y, Fei Z, Zhang X, Shang Y, Li H. Will the markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments. Expert Rev Pharm Out. 2021;21(3):373–380 doi:10.1080/14737167.2021.1893167
   Google Scholar
• Cranmer H, Shields GE, Bullement A. A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. J Med Econ. 2020;23(10):1176–1185. doi:10.1080/13696998.2020.1796360
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9. doi:10.1016/j.jval.2021.11.1351
   PubMed Web of Science ®Google Scholar
• Kashiwa M, Matsushita R. Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer. Int J Clin Pharm-Net. 2023;45(4):875–883. doi:10.1007/s11096-023-01580-2
   PubMed Web of Science ®Google Scholar
• Liu S, Dou L, Wang K, et al. Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma. Front Oncol. 2022;12:899966 doi:10.3389/fonc.2022.899966
   PubMed Web of Science ®Google Scholar
• Shang F, Zhang B, Kang S. Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China. Expert Rev Pharmacoecon Outcomes Res. 2023;23(3):337–343. doi:10.1080/14737167.2023.2170877
   PubMed Web of Science ®Google Scholar
• Zheng Z, Lin J, Zhu H, Cai H. Cost-effectiveness analysis of pembrolizumab plus chemotherapy vs. chemotherapy alone as first-line treatment in patients with esophageal squamous cell carcinoma and PD-L1 CPS of 10 or more. Front Public Health. 2022;10:893387 doi:10.3389/fpubh.2022.893387
   PubMed Web of Science ®Google Scholar
• Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer-Am Cancer Soc. 2015;121(1):8–16 doi:10.1002/cncr.28914
   Google Scholar
• Jiang Y, Li Y, Wang LXW. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Int J Clin Pharm-Net. 2022;44(2):499–506. doi:10.1007/s11096-021-01372-6
   PubMed Web of Science ®Google Scholar
• Shao T, Ren Y, Zhao M, Tang W. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China. Front Public Health. 2022;10:912921 doi:10.3389/fpubh.2022.912921
   PubMed Web of Science ®Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M. Health state utilities in non–small cell lung cancer: an international study. Asia-Pac J Clin Onco. 2017;13(5):e195–203 doi:10.1111/ajco.12477
   PubMed Web of Science ®Google Scholar
• Holleman MS, van Tinteren H, Groen HJM, Al MJ, Uyl-de Groot CA. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. OncoTargets Therapy. 2019;12:1413–1421. doi:10.2147/OTT.S189438
   PubMed Web of Science ®Google Scholar
• Cai Y, Chen W, Wang X, et al. Contemporary trends on expenditure of hospital care on total cancer and its subtypes in China during 2008–2017. Chinese J Cancer Res. 2021;33(5):627–636. doi:10.21147/j.issn.1000-9604.2021.05.09
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao M, Xi J, Li J, Tang W, Zheng X. Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective. Front Public Health. 2023;11:1282374 doi:10.3389/fpubh.2023.1282374
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu Y, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi:10.1016/S0140-6736(18)32409-7
   PubMed Web of Science ®Google Scholar
• Rossi G, Pezzuto A, Sini C, et al. Concomitant medications during immune checkpoint blockage in cancer patients: novel insights in this emerging clinical scenario. Crit Rev Oncol/Hematol. 2019;142:26–34. doi:10.1016/j.critrevonc.2019.07.005
   PubMed Web of Science ®Google Scholar